{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:44:49Z","timestamp":1792514689723,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To review the pharmacology, efficacy, and safety of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea due to\n                      <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                      in adults and pediatric patients 12 years of age and older.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and extraction:<\/jats:title>\n                    <jats:p>A literature search was conducted in Scopus, Web of Science, PubMed Central, Gale Academic FileOne, MEDLINE, Journals@Ovid, and Science Direct databases for all articles relevant to zoliflodacin from inception through February 12, 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>\n                      Preclinical, pharmacokinetic, and clinical trial data have demonstrated that zoliflodacin is effective against multidrug-resistant (MDR)\n                      <jats:italic toggle=\"yes\">N. gonorrhoeae<\/jats:italic>\n                      , with high urogenital cure rates and no current evidence of increasing minimum inhibitory concentrations. Evidence from phase II and III trials supports its single-dose use as an alternative to ceftriaxone; however, the reduced efficacy for pharyngeal and rectal lesions requires additional evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison with existing drugs:<\/jats:title>\n                    <jats:p>Zoliflodacin could serve as an oral alternative to ceftriaxone, particularly for patients with a cephalosporin allergy, and be a viable option for resistance-directed therapy. Continued surveillance will be imperative as zoliflodacin use increases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Zoliflodacin is a novel, first-in-class spiropyrimidinetrione antibiotic for the treatment of uncomplicated urogenital gonorrhea that is efficacious and provides a novel option for MDR\n                      <jats:italic toggle=\"yes\">N. gonorrhoeae.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261447497","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:17:37Z","timestamp":1779949057000},"page":"1211-1219","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Zoliflodacin for Urogenital Gonorrhea Infections"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-4875","authenticated-orcid":false,"given":"Joshua T.","family":"Wollen","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1582-0611","authenticated-orcid":false,"given":"Abdulwhab","family":"Shremo Msdi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-406X","authenticated-orcid":false,"given":"Taryn","family":"Eubank","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. Global and Regional STI Estimates. WHO Global Health Observatory; 2024. Accessed March 12 2026. https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/global-and-regional-sti-estimates"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00171-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","unstructured":"Regan MR McDevitt CJ Robinson LR Issifou S Wadsworth CB. Put your money where your mouth is: surveillance of antibiotic resistance within the commensal Neisseria. bioRxiv. doi:10.64898\/2026.02.14.705939","DOI":"10.64898\/2026.02.14.705939"},{"key":"e_1_3_3_6_2","unstructured":"Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report. CDC Website; 2025. Accessed March 12 2026. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html"},{"key":"e_1_3_3_7_2","unstructured":"Entasis Therapeutics Inc. Nuzolvence prescribing information. Published online December 2025. Accessed March 12 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219491Orig1s000lbl.pdf"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.663534"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.4c00128"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00021"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04124-14"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00786-15"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01479-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706988"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz376"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab262"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01808-18"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1433"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1011"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01953-1"},{"key":"e_1_3_3_21_2","unstructured":"Food and Drug Administration. Uncomplicated gonorrhea: developing drugs for treatment guidance for industry. Published online 2015. Accessed January 13 2026. https:\/\/www.fda.gov\/media\/88904\/download"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.210"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01292-21"},{"key":"e_1_3_3_24_2","unstructured":"Entasis Therapeutics Inc. Nuzolvence principal display panel. Published online January 2026. Accessed March 3 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/getFile.cfm?setid=19e212d6-3861-f40e-afb3-1904eb5bc35b&type=pdf"},{"key":"e_1_3_3_25_2","volume-title":"Guidelines for the Management of Symptomatic Sexually Transmitted Infections","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Guidelines for the Management of Symptomatic Sexually Transmitted Infections. 1st ed. World Health Organization; 2021.","edition":"1"},{"key":"e_1_3_3_26_2","unstructured":"Centers for Disease Control and Prevention. STI Surveillance Network (SSuN). Sexually Transmitted Infections (STIs); 2026. Accessed March 16 2026. https:\/\/www.cdc.gov\/sti\/php\/projects\/ssun.html"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261447497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261447497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261447497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:06Z","timestamp":1792513026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261447497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1177\/10600280261447497"],"URL":"https:\/\/doi.org\/10.1177\/10600280261447497","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}